Cargando…
Lung Adenocarcinoma Tumor Origin: A Guide for Personalized Medicine
SIMPLE SUMMARY: Lung cancer is the leading cause of cancer-related death worldwide, with an average 5-year survival rate of approximately 15%. Among the multiple histological type of lung cancer, adenocarcinoma is the most common. Adenocarcinoma is characterized by a high degree of heterogeneity at...
Autores principales: | Seguin, Laetitia, Durandy, Manon, Feral, Chloe C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996976/ https://www.ncbi.nlm.nih.gov/pubmed/35406531 http://dx.doi.org/10.3390/cancers14071759 |
Ejemplares similares
-
NANOBODY(®) Molecule, a Giga Medical Tool in Nanodimensions
por: Kunz, Sarah, et al.
Publicado: (2023) -
Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer
por: Seguin, Laetitia, et al.
Publicado: (2018) -
A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy
por: Douguet, Laetitia, et al.
Publicado: (2021) -
Promises and challenges of personalized medicine to guide ARDS therapy
por: Wick, Katherine D., et al.
Publicado: (2021) -
Advances in risk stratification of bladder cancer to guide personalized medicine
por: Matulay, Justin T., et al.
Publicado: (2018)